Evaluation of CD4⁺CD25⁺⁄⁻CD39⁺ T-cell populations in peripheral blood of patients following kidney transplantation and during acute allograft rejection
Version 2 2024-06-03, 18:12Version 2 2024-06-03, 18:12
Version 1 2017-08-04, 11:12Version 1 2017-08-04, 11:12
journal contribution
posted on 2024-06-03, 18:12authored byJL McRae, JSJ Chia, SA Pommey, KM Dwyer
Aim: Regulatory T cells (Treg) are important in mediating immune tolerance and outcomes of allotransplantation. CD4 + CD25 + CD39 + co-expression identifies memory Treg; CD4 + CD25 − CD39 + memory T effectors. We sought to determine CD4 + CD25 +/− CD39 + expression from the peripheral blood of patients with end stage renal failure, following transplantation and during episodes of acute cellular rejection. Methods: CD4 + T cells were isolated from peripheral blood leucocytes and analysed for CD25 and CD39 expression by flow cytometry. Treg suppressive function was measured by suppression of autologous effector T-cell proliferation by Treg in co-culture. Results: CD4 + CD25 +/− CD39 + T-cell subsets were tracked longitudinally in the peripheral blood of 17 patients following renal transplantation. Patients with acute T-cell-mediated rejection diagnosed on biopsy had reduced CD4 + CD25 + CD39 + mTreg (P < 0.05) and CD4 + CD25 − CD39 + mTeff (P < 0.01) cells compared with non-rejecting patients. CD4 + CD25 + CD39 + mTreg (P < 0.05) and CD4 + CD25 − CD39 + mTeff (P = 0.057) were reduced in long-term transplant patients ( > 1 year) compared with non-immunosuppressed controls. Interestingly, remaining CD4 + CD25 + CD39 + mTreg in the stable transplant patients displayed more potent suppressive capacity compared with non-immunosuppressed controls (83.2% ± 3.1% vs 45.7% ± 8.0%, nTeff:Treg ratio 8:1, P < 0.01). Conclusion: CD4 + CD25 + CD39 + mTreg and CD4 + CD25 − CD39 + mTeff in peripheral blood can be tracked in renal transplant patients. Acute cellular rejection was accompanied by reduced mTreg and mTeff. Determining changes in these T-cell subsets may help to identify patients with, or at high risk of, renal allograft rejection.